World Health Organization Issues Concern Over Critical Lack of Weight-Loss Medications
Fewer than 10% of individuals who could benefit from weight-loss injections such as Wegovy are able to get them, warns the World Health Organization as it issues its inaugural guidance on the drugs.
Given in excess of 1,000,000,000 people worldwide now obese, it is advocating for broader and more equitable availability to GLP-1 medication.
According to projections, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that obesity is a chronic disease that can be addressed with comprehensive and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are significant obstacles to broad availability to the jabs that can aid individuals in losing significant weight, says the organization.
Skinny Jab Scarcity
Even in the present best projected scenario, the manufacturing of such drugs would only suffice for approximately 100 million people – less than 10% of eligible patients, as stated by the WHO.
The recommendation calls on countries and companies to increase availability, through measures like licensing agreements.
A patent on semaglutide – the primary component of Novo Nordisk's Wegovy – is set to lapse in a number of countries in 2026.
How Weight-Loss Drugs Function
These medications imitate a natural hormone to slow digestion, suppress the appetite and boost satiety so users eat less.
Individuals typically begin shedding pounds after several weeks of commencing the regular doses.
Evidence suggests patients may put most of the weight back on within a year of discontinuing the medication, because their usual appetite come back.
To be overweight or obese raises your risk for experiencing health problems, including diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight impacts individuals in countries worldwide and was linked to millions of fatalities worldwide in 2024, as per the health agency.
